The Online Books Page

Progesterone -- Antagonists

See also what's at your library, or elsewhere.

• Progesterone
• Hormone antagonists
• Antagonists

• Progesterone -- Antagonists -- Government policy
• Mifepristone

• Antagonists, Progesterone
• Antiprogestational agents
• Antiprogesterones
• Antiprogestins
• Progesterone antagonists
• Progestin antagonists

• RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994. (U.S. G.P.O. :, 1994), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)

• RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994. (U.S. G.P.O. :, 1994), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Washington, DC, July 28, 1992. (U.S. G.P.O. :, 1993), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• RU 486 : the import ban and its effect on medical research : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred First Congress, second session, Washington, DC, November 19, 1990. (U.S. G.P.O. :, 1991), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The safety and effectiveness of the abortifacient RU486 in foreign markets : opportunities and obstacles to U.S. commercialization : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, December 5, 1991. (U.S. G.P.O. :, 1992), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)

• RU 486 : the import ban and its effect on medical research : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred First Congress, second session, Washington, DC, November 19, 1990. (U.S. G.P.O. :, 1991), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The safety and effectiveness of the abortifacient RU486 in foreign markets : opportunities and obstacles to U.S. commercialization : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, December 5, 1991. (U.S. G.P.O. :, 1992), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)

• RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994. (U.S. G.P.O. :, 1994), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Washington, DC, July 28, 1992. (U.S. G.P.O. :, 1993), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)

• The safety and effectiveness of the abortifacient RU486 in foreign markets : opportunities and obstacles to U.S. commercialization : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, December 5, 1991. (U.S. G.P.O. :, 1992), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)

• RU 486 (U.S. G.P.O. :, 2007), by Drug Policy United States. Congress. House. Committee on Government Reform. Subcommittee on Criminal Justice (page images at HathiTrust)

Items below (if any) are from related and broader terms.

• RU-486, status report on the U.S. commercialization project, transfer of antiprogestin technology to the United States : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, May 16, 1994. (U.S. G.P.O. :, 1994), by Business Opportunities United States. Congress. House. Committee on Small Business. Subcommittee on Regulation (page images at HathiTrust)
• The role of progesterone during pregnancy in dairy cows (Agricultural Experiment Station, 1970), by T. Y. Tanabe (page images at HathiTrust; US access only)

• Bioidentical hormones : sound science or bad medicine : hearing before the Special Committee on Aging, United States Senate, One Hundred Tenth Congress, first session, Washington, DC, April 19, 2007. (U.S. G.P.O. :, 2007), by United States Senate Special Committee on Aging (page images at HathiTrust)

• Report of the Public Board of Inquiry on Depo-Provera (U.S. Food and Drug Administration, 1984), by Paul D. Stolley, Griff T. Ross, Judith Weisz, and United States Food and Drug Administration (page images at HathiTrust)
• Use of the drug, Depo Provera, by the Indian Health Service : oversight hearing before the Subcommittee on General Oversight and Investigations of the Committee on Interior and Insular Affairs, House of Representatives, One Hundredth Congress, first session ... hearing held in Washington, DC, August 6, 1987. (U.S. G.P.O. :, 1988), by United States. Congress. House. Committee on Interior and Insular Affairs. Subcommittee on General Oversight and Investigations (page images at HathiTrust)

• The Depo-Provera debate : hearings before the Select Committee on Population, U.S. House of Represetatives, Ninety-fifth Congress, second session, August 8, 9, and 10, 1978. (U.S. Govt. Print. Off., 1979), by United States. Congress. House. Select Committee on Population (page images at HathiTrust)

• The Depo-Provera debate : hearings before the Select Committee on Population, U.S. House of Represetatives, Ninety-fifth Congress, second session, August 8, 9, and 10, 1978. (U.S. Govt. Print. Off., 1979), by United States. Congress. House. Select Committee on Population (page images at HathiTrust)

• Adjuvant therapy for breast cancer (National Institutes of Health, 2001), by Md.) National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer (2000 : Bethesda, National Institutes of Health (U.S.). Office of Research on Women's Health, National Institute of Nursing Research (U.S.), National Institutes of Health (U.S.). Office of Medical Applications of Research, and National Cancer Institute (U.S.) (page images at HathiTrust)
• Tamoxifen and breast cancer : hearing before a subcommittee of the Committee on Appropriations, United States Senate, One Hundred Fifth Congress, second session, special hearing. (U.S. G.P.O. :, 1998), by Health and Human Services United States. Congress. House. Committee on Appropriations. Subcommittee on the Departments of Labor (page images at HathiTrust)

• Development of folates and folic acid antagonists in cancer chemotherapy : Innisbrook, Tarpon Springs, Florida, January 23-26, 1986 (U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health ;, 1987), by Peter J. O'Dwyer, Howard W. Bruckner, Lederle Laboratories, Burroughs Wellcome Company, and National Cancer Institute (U.S.) (page images at HathiTrust)

• New drugs used for nonapproved purposes (Methotrexate for psoriasis). Hearings before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-second Congress, first session. July 29 and 30, 1971. (U.S. Govt. Print. Off., 1971), by United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee (page images at HathiTrust)

• Dextromethorphan Distribution Act of 2009 : report (to accompany H.R. 1259) (including cost estimate of the Congressional Budget Office). (U.S. G.P.O., 2009), by United States House. Committee on Energy and Commerce (page images at HathiTrust)

• Thorazine; reference manual. (Smith Kline & French Laboratories, 1958), by Kline & French Laboratories Smith (page images at HathiTrust; US access only)
• Effect of chlorpromazine on survival time in irradiated mice (West Los Angeles, California : University of California, 1955., 1955), by Thomas J. Haley, Eve F. McCulloh, W. G. McCormick, Los Angeles University of California, and U.S. Atomic Energy Commission (page images at HathiTrust)

• LSD-25: a factual account; layman's guide to the pharmacology, physiology, psychology, and sociology of LSD (U.S. Bureau of Narcotics and Dangerous Drugs; [for sale by the Supt. of Docs., U.S. Govt. Print. Off.], 1970), by Louise G. Richards and United States. Bureau of Narcotics and Dangerous Drugs (page images at HathiTrust; US access only)
• Questions and answers : LSD. (Michigan Dept. of Education, 1968), by Michigan. Department of Education (page images at HathiTrust; US access only)
• Narcotics and dangerous drugs : San Diego November 13, 14, and 15, 1963 (The Committee, 1963), by California. Legislature. Assembly. Committee on Criminal Procedure (page images at HathiTrust; US access only)
• Short-term effects of LSD on anxiety, attitudes, and performance [by] William H. McGlothlin [et al.] (Santa Monica, Calif., 1963), by William H McGlothlin (page images at HathiTrust; US access only)
• LSD in the United States. (Drug Enforcement Administration, Strategic Intelligence Section, Domestic Unit, 1995), by United States. Drug Enforcement Administration (page images at HathiTrust)
• LSD : the age of mind (Fulton's Offset Press ;, 1963), by Bernard Roseman, Julio Mario Santo Domingo Collection, and Fitz Hugh Ludlow Memorial Library (page images at HathiTrust; US access only)
• Catalogue of the literature on Delysid-D-lysergic acid diethylamide or LSD 25. (Hanover, N.J. : [publisher not identified], [1958?], 1958), by Sandoz Pharmaceuticals (page images at HathiTrust; US access only)

• Handbook for the Therapeutic Use of Lysergic Acid Diethylamide-25: Individual and Group Procedures (1959), by D. B. Blewett and N Chwelos (HTML and PDF with commentary at maps.org)

• Lysergic acid diethylamide, LSD-25 : a selection of periodical articles ([Washington], 1956), by National Institutes of Health (U.S.). Library Branch and Charlotte Kenton (page images at HathiTrust)

• Adverse reactions to hallucinogenic drugs, with background papers; conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967. (U.S. National Institute of Mental Health; [for sale by Supt. of Docs., U.S. Govt. Print. Off., Washington, 1969), by Roger E. Meyer, National Clearinghouse for Mental Health Information (U.S.), and National Institute of Mental Health (U.S.). Center for Studies of Narcotic and Drug Abuse (page images at HathiTrust)

• Questions and answers : LSD. (Michigan Dept. of Education, 1968), by Michigan. Department of Education (page images at HathiTrust; US access only)

• My self and I. (Coward-McCann, 1962), by Thelma Moss (page images at HathiTrust)
• The discovery of love (Distributed by Dodd, Mead, 1963), by Malden Grange Bishop (page images at HathiTrust)

• Intracerebral injection of lysergic acid diethylamide in conscious dogs and cats (West Los Angeles, California : University of California, 1957., 1957), by Thomas J. Haley, S. R. Dasgupta, Los Angeles University of California, and U.S. Atomic Energy Commission (page images at HathiTrust)

• Handbook for the Therapeutic Use of Lysergic Acid Diethylamide-25: Individual and Group Procedures (1959), by D. B. Blewett and N Chwelos (HTML and PDF with commentary at maps.org)

• LSD follow-up study report. (U.S. Army Medical Department, U.S. Army Health Services Command ;, 1980), by United States. Army Health Services Command (page images at HathiTrust)

• The Effects of reserpine on mature chickens (Oklahoma Agricultural Experiment Station, 1960), by John C. Gilbreath (page images at HathiTrust; US access only)
• Pharmacological effects following intracerebral and intravenous reserpine in conscious mice (West Los Angeles, California : University of California, 1958., 1958), by Thomas J. Haley, S. R. Dasgupta, Los Angeles University of California, and U.S. Atomic Energy Commission (page images at HathiTrust)

• Intraventricular administration of reserpine and its metabolites in conscious cats (West Los Angeles, California : University of California, 1957., 1957), by Thomas J. Haley, S. R. Dasgupta, Los Angeles University of California, and U.S. Atomic Energy Commission (page images at HathiTrust)